Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers

Publisher： John Wiley & Sons Inc

E-ISSN： 2160-7648|4|2|83-88

ISSN： 2160-763X

Source： Clinical Pharmacology In Drug Development, Vol.4, Iss.2, 2015-03, pp. : 83-88

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology

Current Medicinal Chemistry, Vol. 24, Iss. 11, 2017-05 ,pp. : 1158-1167

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetics, Safety, and Tolerability of GLPG0259, a Mitogen-Activated Protein Kinase-Activated Protein Kinase 5 (MAPKAPK5) Inhibitor, Given as Single and Multiple Doses to Healthy Male Subjects

By Namour Florence

Drugs in R&D, Vol. 12, Iss. 3, 2012-09 ,pp. : 141-163

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Single Oral Doses of Apricitabine, a Novel Deoxycytidine Analogue Reverse Transcriptase Inhibitor, in Healthy Volunteers

By Holdich Tom

Clinical Drug Investigation, Vol. 26, Iss. 5, 2006-01 ,pp. : 279-286

Adis International

Access to resources Recommend Favorite

Safety and Clinical Pharmacokinetics of Nemonoxacin, a Novel Non-Fluorinated Quinolone, in Healthy Chinese Volunteers Following Single and Multiple Oral Doses

By Guo Beining Wu Xiaojie Zhang Yingyuan Shi Yaoguo Yu Jicheng Cao Guoying Zhang Jing

Clinical Drug Investigation, Vol. 32, Iss. 7, 2012-07 ,pp. : 475-486

Adis International

Access to resources Recommend Favorite

Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects: A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled Study

By Hu Pei

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 221-228

Adis International

Access to resources Recommend Favorite